Latigo Biotherapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Latigo Biotherapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Thousand Oaks
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LTGO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002056611
- EIN
- 83-2625838
Board of directors
- Since 2026
-
James B. Tananbaum · DirectorSince 2026
-
Kevin Raidy · DirectorSince 2026
-
Nima Farzan · Director · President and CEOSince 2026
-
Sara Bonstein · DirectorSince 2026
- Since 2026
-
Todd N. Smith · DirectorSince 2026
Chief executives
Nima Farzan
· President and CEO
Since August 2026
Board connections
5 of this board's directors also sit on 13 other boards.
- via Beth C. Seidenberg and Timothy P. Walbert
- via James B. Tananbaum
- via Beth C. Seidenberg
- via Timothy P. Walbert
- via Timothy P. Walbert
- via Timothy P. Walbert
- via Nima Farzan
- via Beth C. Seidenberg
- via Timothy P. Walbert
- via Timothy P. Walbert
- via Beth C. Seidenberg
- via Beth C. Seidenberg
- via Sara Bonstein
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $5,040,000
- 2 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 10, 2026 | Foresite Capital Management V, LLC 10% owner | Derivative conversion | +3,117,664 | — | — |
| Aug 10, 2026 | Beth C. Seidenberg Director, 10% owner | Derivative conversion | +938,979 | — | — |
| Aug 10, 2026 | James B. Tananbaum Director, 10% owner | Derivative conversion | +3,117,664 | — | — |
| Aug 10, 2026 | Westlake BioPartners Fund I, L.P. 10% owner | Derivative conversion | +938,979 | — | — |
| Aug 10, 2026 | 5AM Ventures VI, L.P. 10% owner | Derivative conversion | +4,975,543 | — | — |
| Aug 10, 2026 | Sanofi 10% owner | Derivative conversion | +494,800 | — | — |
| Aug 10, 2026 | Foresite Capital Management V, LLC 10% owner | Derivative conversion | +445,320 | — | — |
| Aug 10, 2026 | Beth C. Seidenberg Director, 10% owner | Derivative conversion | +3,547,842 | — | — |
| Aug 10, 2026 | James B. Tananbaum Director, 10% owner | Derivative conversion | +445,320 | — | — |
| Aug 10, 2026 | Westlake BioPartners Fund I, L.P. 10% owner | Derivative conversion | +3,547,842 | — | — |
| Aug 10, 2026 | 5AM Ventures VI, L.P. 10% owner | Derivative conversion | +2,350,419 | — | — |
| Aug 10, 2026 | Sanofi 10% owner | Derivative conversion | +177,978 | — | — |
| Aug 10, 2026 | Foresite Capital Management V, LLC 10% owner | Derivative conversion | +1,125,823 | — | — |
| Aug 10, 2026 | Beth C. Seidenberg Director, 10% owner | Derivative conversion | +1,027,635 | — | — |
| Aug 10, 2026 | James B. Tananbaum Director, 10% owner | Derivative conversion | +1,125,823 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.